252 related articles for article (PubMed ID: 15288975)
21. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
Stewart WC; Sharpe ED; Stewart JA; Holmes KT; Latham KE
Am J Ophthalmol; 2001 Mar; 131(3):339-44. PubMed ID: 11239866
[TBL] [Abstract][Full Text] [Related]
22. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
[TBL] [Abstract][Full Text] [Related]
23. Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.
de Arruda Mello PA; Yannoulis NC; Haque RM
Drug Saf; 2002; 25(8):583-97. PubMed ID: 12113643
[TBL] [Abstract][Full Text] [Related]
24. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.
Cohen JS; Gross RL; Cheetham JK; VanDenburgh AM; Bernstein P; Whitcup SM
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S45-52. PubMed ID: 15016561
[TBL] [Abstract][Full Text] [Related]
25. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
26. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension.
Azuma I; Masuda K; Kitazawa Y; Takase M; Yamamura H
Jpn J Ophthalmol; 1993; 37(4):514-25. PubMed ID: 8145398
[TBL] [Abstract][Full Text] [Related]
27. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
28. Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma.
Gunawardena KA; Crame N; Mertz B; Shams N
Ophthalmologica; 2003; 217(2):129-36. PubMed ID: 12592052
[TBL] [Abstract][Full Text] [Related]
29. A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl.
Kobayashi H; Kobayashi K; Okinami S
J Glaucoma; 2001 Dec; 10(6):487-92. PubMed ID: 11740220
[TBL] [Abstract][Full Text] [Related]
30. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
32. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone.
Susanna R; Medeiros FA; Vessani RM; Giampani J; Borges AS; Jordão ML
J Ocul Pharmacol Ther; 2004 Oct; 20(5):401-10. PubMed ID: 15650515
[TBL] [Abstract][Full Text] [Related]
33. The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol.
Miki H; Miki K
J Ocul Pharmacol Ther; 2004 Dec; 20(6):509-17. PubMed ID: 15684810
[TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
35. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.
Weinreb RN; Caldwell DR; Goode SM; Horwitz BL; Laibovitz R; Shrader CE; Stewart RH; Williams AT
Am J Ophthalmol; 1990 Aug; 110(2):189-92. PubMed ID: 2198812
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of isopropyl unoprostone (Rescula), in the adjunctive treatment of primary open angle glaucoma].
Zarnowski T; Kawa P; Jurkowska-Dudzińska J; Zagórski Z
Klin Oczna; 2001; 103(1):13-5. PubMed ID: 11605578
[TBL] [Abstract][Full Text] [Related]
37. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
[TBL] [Abstract][Full Text] [Related]
38. Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation.
Zhan GL; Toris CB; Meza JL; Camras CB
J Glaucoma; 2003 Aug; 12(4):383-9. PubMed ID: 12897587
[TBL] [Abstract][Full Text] [Related]
39. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
[TBL] [Abstract][Full Text] [Related]
40. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
Latanoprost-Induced Iris Pigmentation Study Group
Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
